Group 1 - Paysign, Inc. (PAYS) closed at $5.09, with a 42.4% gain over the past four weeks, and analysts set a mean price target of $7.35, indicating a 44.4% upside potential [1][2] - The mean estimate includes five short-term price targets with a standard deviation of $0.74, where the lowest estimate is $6.50 (27.7% increase) and the highest is $8.25 (62.1% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a powerful predictor of potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.1%, with one estimate moving higher and no negative revisions [12] - PAYS has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential upside [13] - While the consensus price target may not be reliable for predicting the extent of gains, it does provide a good directional guide for price movement [14]

Group 1 - ZipRecruiter, Inc. (ZIP) shares have increased by 43.4% over the past four weeks, closing at $6.25, with a mean price target of $8 indicating a potential upside of 28% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $1.87, where the lowest estimate is $6 (4% decline) and the highest is $10 (60% increase) [2] - Analysts show a strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 1.1% over the past month, with two estimates increasing and one decreasing [12] - ZIP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]

Core Viewpoint - Brainsway Ltd. (BWAY) has shown a significant price increase of 20.1% over the past four weeks, with a mean price target of $15.05 indicating a potential upside of 43.9% from its current price of $10.46 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.74, where the lowest estimate is $14.20 (35.8% increase) and the highest is $16 (53% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can be a useful starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about BWAY's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - Over the last 30 days, three earnings estimates have been revised higher, resulting in a 13% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - BWAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

日本央行行长植田和男：将通过实现价格目标来确保对日本央行的信任。 ...

Group 1 - The core viewpoint is that Inspired Entertainment (INSE) has significant upside potential, with a mean price target of $12.40 indicating a 56.6% increase from its current price of $7.92 [1] - Analysts have set short-term price targets ranging from $10 to $16, with the lowest estimate suggesting a 26.3% increase and the highest indicating a 102% upside [2] - The standard deviation of $2.30 among the price targets suggests a moderate level of agreement among analysts regarding the stock's potential movement [2] Group 2 - Analysts are optimistic about INSE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 78.3%, with two estimates moving higher and no negative revisions [12] - INSE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Summit Therapeutics PLC (SMMT) closed the last trading session at $25.85, gaining 10.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $37.38 indicates a 44.6% upside potential.The average comprises eight short-term price targets ranging from a low of $30 to a high of $44, with a standard deviation of $5.71. While the lowest estimate indicates an increase of 16.1% from the current ...

Core Viewpoint - Kontoor Brands (KTB) has shown a significant price increase of 13.3% over the past four weeks, with a mean price target of $87.83 indicating a potential upside of 26.2% from the current price of $69.62 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $9.22, suggesting variability in analyst predictions. The lowest estimate of $72 indicates a 3.4% increase, while the highest estimate suggests a 43.6% surge to $100 [2] - Analysts' price targets can often mislead investors, as empirical research shows that these targets rarely indicate actual stock price movements [7][10] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding KTB's ability to report better earnings than previously predicted, which supports the expectation of an upside in the stock [4][11] - The Zacks Consensus Estimate for the current year has increased by 2.9% over the past month, with one estimate rising and no negative revisions [12] - KTB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for near-term upside [13]

Group 1 - Immunome, Inc. (IMNM) shares have increased by 1.1% over the past four weeks, closing at $8.49, with a mean price target of $24.50 indicating a potential upside of 188.6% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, where the lowest estimate of $20 suggests a 135.6% increase, and the highest estimate predicts a surge of 347.6% to $38 [2] - Analysts show a consensus that IMNM will report better earnings than previously estimated, which strengthens the outlook for the stock [4][11] Group 2 - Over the last 30 days, five earnings estimates for IMNM have been revised upward, resulting in a Zacks Consensus Estimate increase of 17.9% [12] - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - The correlation between earnings estimate revisions and near-term stock price movements suggests that the positive trend in earnings estimates could lead to stock price increases [11]

Group 1 - Nova Ltd. (NVMI) closed at $190.17, with a 10% gain over the past four weeks, and a mean price target of $255.83 suggests a 34.5% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $19.60, indicating variability among analysts; the lowest estimate is $235 (23.6% increase), while the highest is $280 (47.2% increase) [2] - Analysts show strong agreement on NVMI's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for NVMI has increased by 3.6% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - NVMI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [13]

Core Viewpoint - EverQuote (EVER) shares have increased by 12.7% in the past four weeks, closing at $23.99, with a potential upside of 42.4% based on Wall Street analysts' mean price target of $34.17 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.79, indicating variability among analysts; the lowest estimate of $30 suggests a 25.1% increase, while the highest target of $38 indicates a potential surge of 58.4% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about EverQuote's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [11][12] - The company holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which further supports the potential upside for the stock [13]